

Amendments to the Specification:

Please replace Table I on page 20 of the present specification with the following Table I:

Table: 1 Combined therapy induces tumour-specific immunity ^a					
Tumour cells Injected	Mice challenged with tumour cells	Challenge dose	Tumour incidence	Tumour onset (days) tumour size <0.2 cm	Time of sacrifice (days) ^b (tumour size <1.0 cm)
EL4	EL4	1X10 ⁴	0/6	-	-
		1X10 ⁵	0/6	-	-
		1X10 ⁷	0/6	-	-
	LLC	1X10 ⁴	5/5	16-24	35±4.2
		1X10 ⁵	5/5	14-20	30±5.1
		1X10 ⁷	5/5	14-19	29±4.3
LLC	LLC	1X10 ⁴	0/6	-	-
		1X10 ⁵	0/6	-	-
		1X10 ⁷	1/6	-	29
	EL-4	1X10 ⁴	5/5	18-26	38±6.1
		1X10 ⁵	5/5	16-22	36±6.1
		1X10 ⁷	5/5	16-24	33±4.5

^a Tumors were established with EL4 or LLC tumor cells and B7.1 DNA injected intratumorally, Twenty-four hours later, DMXAA was administered i.p. and after 21 days animals were challenged.

^b Values represent means ±SD, calculated from 5 or 6 mice per group.